Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.
World J Gastrointest Oncol. Sep 15, 2026; 18(9): 119632
Published online Sep 15, 2026. doi: 10.4251/wjgo.119632
Published online Sep 15, 2026. doi: 10.4251/wjgo.119632
Triplet vs doublet adjuvant chemotherapy for gastric cancer: A systematic review and meta-analysis
Chang-Tao Yu, Department of General Surgery, The Second People’s Hospital of Liaocheng, Liaocheng 252600, Shandong Province, China
Jin-Kai Wang, Department of Gastrointestinal Surgery, The Second People’s Hospital of Liaocheng, Liaocheng 252600, Shandong Province, China
Bai-Xue Qin, Center of Digestive Endoscopy, The Second People’s Hospital of Liaocheng, Liaocheng 252600, Shandong Province, China
Guang-Yuan Wang, Department of Gastroenterology, The Second People’s Hospital of Liao
Co-first authors: Chang-Tao Yu and Jin-Kai Wang.
Author contributions: Yu CT and Wang JK contributed equally to this work as co-first authors and they were responsible for the conception and design of the study, performed the systematic literature search, conducted data extraction and quality assessment, and drafted the initial manuscript; Qin BX participated in the literature screening, assisted with data verification, and contributed to the methodological review of included studies; Wang GY supervised the project, performed the statistical analysis and meta-analysis, interpreted the results, and critically revised the manuscript for important intellectual content; and all authors have read and approved the final version of the manuscript.
AI contribution statement: The authors used ChatGPT for language editing and grammar improvement during manuscript preparation. The authors reviewed and revised all AI-assisted content and take full responsibility for the accuracy, integrity, and scientific validity of the manuscript.
Conflict-of-interest statement: The authors declare that they have no conflicts of interest related to this study.
PRISMA 2009 Checklist statement: The authors have read the PRISMA 2009 Checklist, and the manuscript was prepared and revised according to the PRISMA 2009 Checklist.
Corresponding author: Guang-Yuan Wang, MD, Department of Gastroenterology, The Second People’s Hospital of Liaocheng, No. 306 Jiankang Street, Xianfeng Subdistrict Office, Liaocheng 252600, Shandong Province, China. guangyuanwang2025@163.com
Received: March 25, 2026
Revised: June 2, 2026
Accepted: June 23, 2026
Published online: September 15, 2026
Processing time: 153 Days and 5 Hours
Revised: June 2, 2026
Accepted: June 23, 2026
Published online: September 15, 2026
Processing time: 153 Days and 5 Hours
Core Tip
Core Tip: This comprehensive meta-analysis of 12 randomized controlled trials encompassing 11126 patients demonstrates that taxane-platinum-fluoropyrimidine triplet chemotherapy significantly improves objective response rate (1.73-fold increase) and disease control rate (1.22-fold increase) compared to platinum-fluoropyrimidine doublet regimens in neoadjuvant treatment of gastric cancer. Despite superior tumor response, no significant survival benefits were observed. Importantly, safety profiles were comparable between regimens. These findings support individualized treatment selection, with triplet regimens preferred for maximal tumor downstaging when surgical resectability is borderline.